London, UK, 8 February 2007: BioProgress plc (‘BioProgress’ or the ‘Company’) (AIM: BPRG; NASDAQ: BPRG), the speciality pharmaceutical and healthcare company, has today announced that it has agreed, subject to final contract, to in-license MuGard(TM) (the “Product”) from Access Pharmaceuticals Inc (“Access”).
